These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26139424)

  • 1. Editorial: the vital role of randomized controlled trials in Arthritis & Rheumatology.
    Solomon DH; Weinblatt ME; Bucala RJ
    Arthritis Rheumatol; 2015 Oct; 67(10):2555-6. PubMed ID: 26139424
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
    Mariette X
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
    [No Abstract]   [Full Text] [Related]  

  • 3. [Non-TNF biologicals in therapy].
    Wollenhaupt J; Burmester GR
    Z Rheumatol; 2010 Sep; 69(7):579-80. PubMed ID: 20703491
    [No Abstract]   [Full Text] [Related]  

  • 4. Setting the research agenda for future clinical trials on the use of biologics in rheumatology.
    Silman A; Rudkin S; Walley T
    Rheumatology (Oxford); 2011 Aug; 50(8):1356-7. PubMed ID: 21118870
    [No Abstract]   [Full Text] [Related]  

  • 5. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials in rheumatology. Does one size fit all?
    Tombetti E; Rovere-Querini P; Manfredi AA
    Rheumatology (Oxford); 2017 May; 56(5):675-676. PubMed ID: 27313279
    [No Abstract]   [Full Text] [Related]  

  • 7. [TNF-alpha antagonists in therapy of rheumatoid arthritis].
    Gross WL; Gause A
    Z Rheumatol; 2003 Jun; 62(3):217. PubMed ID: 12931691
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of biologics in rheumatology: improving the evidence base.
    Silman AJ; Ades AE
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv1-2. PubMed ID: 21859699
    [No Abstract]   [Full Text] [Related]  

  • 9. Are individual patient trials (n-of-1 trials) in rheumatology worth the extra effort?
    Peloso PM
    J Rheumatol; 2004 Jan; 31(1):8-11. PubMed ID: 14705210
    [No Abstract]   [Full Text] [Related]  

  • 10. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
    [No Abstract]   [Full Text] [Related]  

  • 11. Biological agents and tuberculosis: risk estimates and screening strategies.
    Dobler CC
    Int J Rheum Dis; 2015 Mar; 18(3):264-7. PubMed ID: 25923605
    [No Abstract]   [Full Text] [Related]  

  • 12. [Evidence based medicine in rheumatology].
    Gause A; Raspe HH
    Z Rheumatol; 2002 Oct; 61(5):516-8. PubMed ID: 12399877
    [No Abstract]   [Full Text] [Related]  

  • 13. The Corrona US registry of rheumatic and autoimmune diseases.
    Kremer JM
    Clin Exp Rheumatol; 2016; 34(5 Suppl 101):S96-S99. PubMed ID: 27762197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of biologic agents in rheumatoid arthritis: introduction.
    Silman AJ
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv3-4. PubMed ID: 21859703
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
    Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society].
    Salvarani C; Olivieri I; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M
    Reumatismo; 2004; 56(3):133-4, 136-8. PubMed ID: 15470517
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic strategies: Ways to remission].
    Krüger K; Edelmann E
    Z Rheumatol; 2015 Jun; 74(5):386-7. PubMed ID: 26085071
    [No Abstract]   [Full Text] [Related]  

  • 18. William S. Clark, first editor of Arthritis and Rheumatism.
    Mannik M
    Arthritis Rheum; 2008 Feb; 58(2 Suppl):S11-4. PubMed ID: 18240164
    [No Abstract]   [Full Text] [Related]  

  • 19. [Do DMARDs contibute to impaired healing after surgery? Should they be discontinued before surgery?].
    Glück T; Müller-Ladner U
    Dtsch Med Wochenschr; 2007 Sep; 132(37):1901-4. PubMed ID: 17823884
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanism of action of tumor necrosis factor antagonists. Proceedings of the Canadian expert roundtable meeting, Banff, Canada, November 28-30, 2003.
    J Rheumatol Suppl; 2005 Mar; 74():1-47. PubMed ID: 15742456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.